

# Progestin Dominant Impact Consolidatedoral Contraception on Advancement of Uterine Fibroids

WARDA SAJJAL<sup>1</sup>, ISMA KHALID<sup>2</sup>, AMANA FATIMA<sup>3</sup>, ABEERA MERIUM<sup>4</sup>

<sup>1-4</sup>Consultants, Department of Obstetrics & Gynaecology, Women Christian Hospital Multan  
Correspondence to: Dr. Warda Sajjal, E-mail: [sajjalwarda@gmail.com](mailto:sajjalwarda@gmail.com), Cell: 0334-6043102

## ABSTRACT

**Background and objectives:** Fibroids are the most well-known tumors of the female pelvis. The tumors are considerate and happen in roughly 30% to half of ladies more than 35 years of age, and all the more habitually in individuals of color. The main objective of this study was to analyse the progestin dominant impact consolidatedoral contraception on advancement of uterine fibroids.

**Material and methods:** This randomized controlled trial was conducted at Women Christian Hospital Multan during from July 2019 to July 2020. The data was collected from 50 patients who were suffering from uterine fibroids and they all treated with combined oral contraception.

**Results:** The data was collected from 50 patients. 20 patients were considered in control group for comparison with study group. The patients treated with COC didn't have any clinical issues. In 13 patients (13.4%) under monophasic joined pills, the development of fibroids just as issues like menorrhagia, pallor, stomach agony and dysmenorrhea proceeded or expanded. Fundamental issue in 10 patients was serious uterine dying (surmised blood loss of 300ml), 3 experienced stomach and pelvic pain.

**Conclusion:** It is concluded that uterine fibroids are very common. Numerous ladies need no mediation for their fibroids. Numerous ladies just need traditionalist treatment.

---

## INTRODUCTION

Fibroids are the most well-known tumors of the female pelvis. The tumors are considerate and happen in roughly 30% to half of ladies more than 35 years of age, and all the more habitually in individuals of color. The pathogenesis of fibroids stays muddled, in spite of the fact that fibroid development is believed to be related to hereditary qualities, steroid hormones, and development factors. The area and size of fibroids in the uterus are determinants of their clinical manifestations<sup>1</sup>. By far most of the tumors are asymptomatic and subsequently require no treatment. Draining coming about because of the presence of fibroids is one of the most regularly detailed indications in patients with fibroids, and it has all the earmarks of being related with histological and hormonal changes in the endometrial tissue that lead to vascular destabilization of the endometrium and unpredictable bleeding<sup>2</sup>.

Other revealed indications incorporate pelvic weight or torment, urinary issues, obstruction, just as fruitlessness and repetitive pregnancy misfortune. Subsequently, both the monetary expense and the impact on the personal satisfaction are considerable. Medical procedure has been the pillar of fibroid therapy, albeit different insignificantly intrusive systems have been grown, for example, uterine corridor embolisation, attractive reverberation imaging-guided high-force centered ultrasound, laparoscopic impediment of uterine veins, myolysis, and ulipristal acetic acid derivation pharmacological treatment<sup>3</sup>. It has been indicated that uterine fibroids have essentially expanded convergences of both estrogen and progesterone receptors contrasted and ordinary myometrium.

Joined hormonal (estrogen-progestin) contraception offers numerous non-preventative benefits<sup>4</sup>. The good defensive and helpful impacts containing some gynecological just as nongynecological messes are proof based and regularly utilized in clinical practice. Among the

most significant non-preventative advantages are the decrease of the danger of ovarian, endometrial and colorectal malignant growth, treatment of menorrhagia, dysmenorrhea, and premenstrual condition, skin break out vulgaris, endometriosis and uterine fibroids. Something else, other hormonal prophylactic techniques offering a few advantages are likewise available<sup>5</sup>.

Uterine fibroid is a favorable, mesenchymal tumor generally beginning in smooth muscle of the uterus. It is the most common tumor that happens in over 20% of ladies over 30 years old and in 30-40% of ladies in old age. Leiomyoma is uncommon before menarche, suddenly lessens, and may even blur after menopause<sup>6</sup>.

The main objective of this study was to analyse the progestin dominant impact consolidatedoral contraception on advancement of uterine fibroids.

## MATERIAL AND METHODS

This randomized controlled trial was conducted at women Christian hospital Multan during July 2019 to July 2020. The data was collected from 50 patients who were suffering from uterine fibroids and they all treated with combined oral contraception. Dilatation and curretage for danger avoidance was performed before starting hormonal treatment just in instances of metrorrhagia. The COC was regulated in a regular 21-day routine with a 7-day delay.

The data was gathered into two sections, one was control gathering and one was study gathering. The ultrasound for discovery and estimation of fibroids was utilized. Prior to starting the investigation and at every 3 months following the main seven day stretch of feminine dying, an ultrasound assessment and estimation of fibroids was performed. The data was collected and analysed using SPSS 19. P<0.05 was considered to be statically significant.

## RESULTS

The data was collected from 50 patients. 20 patients were considered in control group for comparison with study group. The patients treated with COC didn't have any clinical issues. In 13 patients (13.4%) under monophasic joined pills, the development of fibroids just as issues like menorrhagia, pallor, stomach agony and dysmenorrhea proceeded or expanded. Fundamental issue in 10 patients was serious uterine dying (surmised blood loss of 300ml), 3 experienced stomach and pelvic pain. They went through activity: in 3 cases myoma enucleation and in 10 cases laparoscopically helped vaginal hysterectomy was performed. Ladies as of now utilizing oral contraceptives have a 1.91-overlap more serious danger of uterine leiomyoma than ladies who never utilized oral contraceptives. Multivariate calculated relapse examination indicated that the frequency of uterine leiomyoma in ladies of childbearing age with oral contraceptives and BMI  $\geq$  25 kg/m<sup>2</sup> was marginally expanded.

## DISCUSSION

There are different hormonal therapies that can be used to temporarily relieve heavy menstrual bleeding and pain. These medicines can likewise recoil fibroids, yet they can't cause them to vanish totally. Hormones are typically just utilized for a restricted measure of time due to the danger of results. However, the treatment just works however long it is utilized, so the fibroids may develop again once it is stopped<sup>7</sup>.

GnRH analogs are falsely delivered hormones. They repress the creation of estrogen in the ovaries. Since estrogen makes it simpler for fibroids to develop, utilizing GnRH analogs can briefly slow their development or cause them to shrivel. GnRH analogs are generally infused into skin or muscle tissue once per month. They are likewise accessible as warehouse (slow-discharge) infusions that keep going for a quarter of a year, and a nasal shower for everyday use. GnRH analogs aren't appropriate for long haul use due to their side effects<sup>8</sup>. They can build the danger of osteoporosis (loss of bone mass) in the event that they are utilized for longer than around one year. They additionally diminish the body's creation of estrogen so much that it is beyond the realm of imagination to expect to get pregnant while utilizing them. At the point when treatment with GnRH analogs is halted, the ovaries begin working ordinarily again and estrogen levels getting back to ordinary levels. At that point it's conceivable to get pregnant once more. During this treatment, it's essential to have the size of the fibroids checked by a specialist and watch out for whether your indications change. This additionally incorporates looking for results, since estrogen lack may cause problems<sup>9</sup>.

**Hormonal intrauterine devices:** Hormonal intrauterine devices (IUDs) are embedded into the belly (uterus) and can stay there for as long as five years. Otherwise called hormonal curls, they are ordinarily utilized for contraception. They contain fake hormones called progestins which are like the female sex hormone

progesterone<sup>10</sup>. Progesterone keeps the arranging of the belly from working during the monthly cycle. Hormonal IUDs constantly discharge progestins, which additionally keep the arranging of the belly from building. Hormonal IUDs are just appropriate for treating fibroids that aren't too enormous. Bigger fibroids may change the state of the belly, making it difficult to embed an IUD. What's more, since they have a preventative impact, IUDs are likewise not a smart thought for ladies who might want to become pregnant<sup>11</sup>.

## CONCLUSION

It is concluded that uterine fibroids are very common. Numerous ladies need no mediation for their fibroids. Numerous ladies just need traditionalist treatment. This can be clinical treatment or careful. The administration of uterine fibroids requires the parity of the intricacies of the fibroids versus the dangers of the treatment choices.

## REFERENCES

1. Tamaya T, Fujimoto J, Okada H. Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium. *Acta Obstet Gynecol Scand.* 1985;64:307–309.
2. Bayer LL, Hillard PJA. Use of levonorgestrel intrauterine system for medical indications in adolescents. *J Adolesc Heal.* 2013;52:S54–S58.
3. Starczewski A, Iwanicki M. Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids. *Ginekol Pol.* 2000;71:1221–1225.
4. Tasci Y, Caglar GS, Kayikcioglu F, et al. Treatment of menorrhagia with the levonorgestrel releasing intrauterine system: effects on ovarian function and uterus. *Arch Gynecol Obstet.* 2009;280:39–42.
5. Magalhães J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. *Contraception.* 2007;75:193–198.
6. Fong YF, Singh K. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient. *Contraception.* 1999;60:51–53.
7. Kaunitz AM. Progestin-releasing intrauterine systems and leiomyoma. *Contraception.* 2007;75:S130–S133.
8. Talaulikar VS, Manyonda I. Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids. *Eur J Obstet Gynecol Reprod Biol.* 2012;165:135–140.
9. Jiang W, Shen Q, Chen M, et al. Levonorgestrel-releasing intrauterine system use in premenopausal women with symptomatic uterine leiomyoma: A systematic review. *Steroids.* 2014;86:69–78.
10. Pavlovich SV, Volkov NI, Burlev VA. Proliferative activity and level of steroid hormone receptors in the myometrium and myoma nodes in different phases of menstrual cycle. *Bull Exp Biol Med.* 2003;136:396–398.
11. Xu Q, Qiu L, Zhu L, et al. Levonorgestrel inhibits proliferation and induces apoptosis in uterine leiomyoma cells. *Contraception.* 2010;82:301–308.